Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
The ITAC (INSIGHT 013) Study Group
Internal Medicine
Infectious Diseases
Research output
:
Contribution to journal
›
Article
›
peer-review
43
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Intravenous Immunoglobulins
100%
Immunoglobulins
78%
Placebos
61%
SARS Virus
39%
GS-5734
38%
Safety
26%
Neutralizing Antibodies
17%
Passive Immunization
10%
Intention to Treat Analysis
10%
Antibodies
9%
National Institutes of Health (U.S.)
9%
Pharmacy
9%
Pharmacists
8%
Random Allocation
8%
Standard of Care
8%
Infections
8%
Intention
8%
Disease Outbreaks
7%
Appointments and Schedules
7%
Tissue Donors
7%
Research Personnel
6%
Randomized Controlled Trials
6%
Lung
4%
Therapeutics
4%
Population
3%